GLP-1 RA Drug Use in Women Reveals Gaps in Safety and Access

Lancet Review Analyzes GLP-1 RA Drug Use in Women

A review in The Lancet Obstetrics, Gynaecology & Women's Health reports that women respond differently to glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications than men. The paper was presented at the 2026 Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan by Professor Paul Franks, Professor Claire Meek, and their coauthors.

The authors issued a call to action to improve the evidence base for female patients worldwide. Global Burden of Disease data cited in the paper estimated the 2021 global prevalence of overweight or obesity at 46.7% in females and 43.4% in males. Those figures are projected to reach 60.3% in females and 57.4% in males by 2050, with the widest gender differences occurring in low- and middle-income countries (LMICs).

Biological Mechanisms Drive Greater Weight Reduction in Females

Biological differences produce greater average weight reduction in female patients receiving GLP-1 RA treatment, even though blood sugar improvements remain comparable between sexes. Women show higher systemic drug exposure than men after adjusting for total body mass.

Women also experience enhanced suppression of food-motivated behaviors and greater reduction of palatable food intake during treatment. Preclinical studies cited by the authors suggest possible interactions between estrogen and GLP-1 receptor signaling pathways.

Real-World Registries Document Higher Adverse Event Frequencies

Observational records show women report adverse events more frequently than men while taking GLP-1 RA prescriptions. Although randomized placebo-controlled trials showed similar side-effect rates between sexes, observational studies document higher female rates of headache, vomiting, and dizziness.

Trial evidence supports the general psychiatric safety of these medications, but the authors recommend routine screening. Clinicians should evaluate patients for depression, anxiety, and eating disorders before starting treatment and throughout follow-up care.

Cessation Risks and Global Cost Barriers Disproportionately Affect Women

Rapid weight regain after stopping GLP-1 RA medications presents distinct physical risks for female body composition. Regaining fat mass without recovering lean muscle raises concerns regarding long-term physical function and metabolic health.

Financial barriers also restrict treatment availability. Independent manufacturing analyses indicate oral semaglutide could cost below $1 per month to produce, and injectable versions below $5 per month.

Nearly 80% of eligible adults live in LMICs where retail prices exceed $90 per month. Women in those regions frequently rely on out-of-pocket spending, which places the medication beyond their reach.

• Polyendocrine metabolic ovarian syndrome (PMOS, formerly polycystic ovary syndrome) affects approximately 12% of women globally, with the highest prevalence in the eastern Mediterranean and south-east Asia.
• Women with type 2 diabetes in LMICs are frequently lean, as diabetes onset occurs at lower body mass index (BMI) thresholds than in populations of European ancestry.

Evidence Gaps Require Targeted Clinical Trials

The authors emphasize that current clinical guidelines rely on data sets that underrepresent specific female populations. More studies are required to establish sex-specific dosing, evaluate body composition shifts during weight regain, and quantify side-effect profiles.

Patients considering these therapies should discuss personal risk factors with a clinician. That assessment should include an evaluation of baseline mental health, nutritional habits, and long-term treatment plans.